We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00002362
Recruitment Status : Suspended
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
Sponsor:
Information provided by:

November 2, 1999
August 31, 2001
June 24, 2005
August 1999
Not Provided
Not Provided
Not Provided
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs
A Randomized, Open-Label Superiority Trial Comparing Emtricitabine to Abacavir Within a Triple Drug Combination in Antiretroviral-Drug Naive HIV-1 Infected Patients
This study will look at whether emtricitabine is as safe and effective as abacavir (ABC) when taken with stavudine (d4T) and efavirenz (EFV) in patients who have never taken anti-HIV drugs.
Patients are randomized to receive open-label emtricitabine or ABC in combination with stavudine and efavirenz. Viral load and CD4+ cell counts are compared at Weeks 24 and 48. Patients are followed for 48 weeks.
Interventional
Phase 3
Primary Purpose: Treatment
HIV Infections
  • Drug: Abacavir sulfate
  • Drug: Efavirenz
  • Drug: Emtricitabine
  • Drug: Stavudine
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Suspended
Not Provided
Not Provided
Not Provided

Inclusion Criteria

You may be eligible if you:

  • Are HIV-positive and generally healthy.
  • Have a viral load of 5,000 copies/ml or more.
  • Have CD4 cell counts of 200 cells/mm3 or more.
  • Are age 18 or older.
  • Agree to practice sexual abstinence or use effective barrier methods of birth control (such as condoms).

Exclusion Criteria

You will not be eligible if you:

  • Have ever taken anti-HIV drugs for 3 days or more.
  • Have had certain AIDS-related infections.
  • Have had severe diarrhea within the past 30 days.
  • Are unable to eat at least 1 meal a day due to nausea, vomiting, or stomach pain.
  • Are being treated for active tuberculosis (TB).
  • Are pregnant or breast-feeding.
  • Use illegal drugs or alcohol that make it difficult for you to take study drugs or keep clinic appointments.
  • Are taking certain medications, or have certain other conditions or diseases (see the technical summary for more detail).
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00002362
298B
FTC-301
Not Provided
Not Provided
Not Provided
Not Provided
Triangle Pharmaceuticals
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
March 2000

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP